title: [Myrin P in the combined treatment of tuberculosis].
abstract: Experimental and clinical evaluation of the new antimycobacterial quadrocomposition Myrin P was performed. The composition consists of isoniazid, rifampicin, pyrazinamide and ethambutol in fixed doses. The results of the formulation application at 474 patients with primary pulmonary tuberculosis caused by drug-susceptible and drug-resistant mycobacteria are presented. High efficacy and good tolerability of the formulation was demonstrated.
authors.affiliation: Research Institute of Phtisiopulmonology, I.M. Sechenov Moscow Medical Academy, Moscow.
authors.forename: G B
authors.initials: GB
authors.lastname: Sokolova
authors.forename: O V
authors.initials: OV
authors.lastname: Semenova
authors.forename: I V
authors.initials: IV
authors.lastname: Bogadel'nikova
authors.forename: A D
authors.initials: AD
authors.lastname: Kunichan
authors.forename: L R
authors.initials: LR
authors.lastname: Zeliger
authors.forename: N A
authors.initials: NA
authors.lastname: Elistratova
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D004977:Ethambutol / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D004338:Drug Combinations; C469386:Myrin P; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin